Business
Enveric Biosciences Participating in BIO-Europe Spring®
CAMBRIDGE, Mass., March 17, 2025--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced its participation in BIO-Europe Spring®, which is being held in Milan, Italy, March 17-19, 2025.
About this update from Enveric Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/8b278a78e217f82237c8d83be1e30aad"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/sEkHKhVLMNYzAOkq1RcoLA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8b278a78e217f82237c8d83be1e30aad","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/dK7pk3jZvwbAp0g2utKkAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/8b278a78e217f82237c8d83be1e30aad","width":1024,"height":512}},"lazy":false},{"type":"text","content":"CAMBRIDGE, Mass., March 17, 2025--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced its participation in BIO-Europe Spring®, which is being held in Milan, Italy, March 17-19, 2025.","length":428,"tagName":"p"},{"type":"text","content":"During the Spring partnering event, members of Enveric’s management team are conducting one-on-one meetings with registered investors and potential partners, showcasing the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.","length":285,"tagName":"p"},{"type":"text","content":""We anticipate a highly productive meeting at BIO-Europe Spring as we continue to garner interest in our strategic approach to developing neuroplastogenic molecules, led by EB-003, for the treatment of underserved mental health conditions. Our ongoing discussions with leaders in the pharmaceutical industry clearly indicate that eliminating or substantially reducing the hallucinatory effect common to N,N-Dimethyltryptamine (DMT), mescaline and related analogs will be key to commercial success," said Joseph Tucker, Ph.D., Director and Chief Executive Officer of Enveric.","length":584,"tagName":"p"},{"type":"text","content":"About Enveric Biosciences","length":25,"tagName":"p"},{"type":"text","content":"Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the de...